A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor Perindopril and its active metabolite in plasma and urine: Advantages of a lysine derivative as immunogen to improve the assay specificity

Abstract

A new radioimmunoassay (RIA) was developed for the direct measurement of perindoprilat (PT), the active metabolite (diacid) of Perindopril (P), an angiotensin-converting enzyme (ACE) inhibitor. Antibodies were raised in rabbits against the lysine derivative of PT conjugated to bovine serum albumin. The p-hydroxyphenyl derivative of the lysine analogue was used for preparation of the radioligand by iodination (¹²⁵I). Cross-reactivities for the glucuronide metabolites of P and PT are low (0.25 and 3.5%, respectively). The theoretical limit of detection is 0.2 nM, the sensitivity attainable with random samples is about 0.5 nM. Within- and between-assay variabilities observed were 4.2–6.7 and 2.8–5.9%, respectively (concentration range 2.1–41.7 nM). Serial dilution of plasma and urine samples showed excellent parallelism (r > 0.95; P < 0.001). Recoveries of PT spiked to urine and plasma samples were 90–120%. The prodrug P can be measured in the same sample (plasma/urine) after chromatographic separation on a Dowex AG 1 × 2 anion-exchange column and quantitative alkaline hydrolysis of the P-containing fraction. It is concluded that the specificity and sensitivity of this assay are amply sufficient for pharmacokinetic studies and in patient monitoring.